Literature DB >> 12566106

Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts.

Dominic C H Ng1, Naomi W Court, Cristobal G dos Remedios, Marie A Bogoyevitch.   

Abstract

OBJECTIVES: The signal transduction pathways mediating the progression to failure have been intensively studied in a variety of in vitro and in vivo animal models. Recently, acute activation of the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) has been observed in the heart, but whether this is sustained in ischemic heart disease (IHD) or dilated cardiomyopathy (DCM) has not been previously addressed.
METHODS: We assessed the tyrosine phosphorylation of STAT1, 3, 5 and 6 in ventricular samples of explanted human hearts with IHD (n=11) and DCM (n=9) as an indication of STAT activation. Samples from normal donor hearts (n=9) acted as controls. In parallel, we also assessed protein expression and phosphorylation of three major families of mitogen-activated protein kinases (MAPKs); ERK, p38 MAPK and c-Jun NH(2)-terminal kinase (JNK).
RESULTS: All STAT isoforms were significantly phosphorylated in DCM. In contrast, only the phosphorylation of STATs 1 and 5 were significantly enhanced in IHD. Expression of total STAT protein remained unchanged. For the MAPKs, significant phosphorylation of p38(MAPK) was only observed in IHD. In contrast, there was no change in ERK or JNK activation despite abundant protein expression.
CONCLUSIONS: We have shown that different members of the STAT transcription factor family are chronically phosphorylated in the failing heart as a result of IHD (STAT1 and 5) or DCM (STAT1, 3, 5 and 6). In contrast, IHD but not DCM showed significant p38(MAPK) phosphorylation. Whilst the differences noted between IHD and DCM may reflect different initiating events, the common activation of STATs 1 and 5 suggests that these transcription factors may play a common role regulating the progression of heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566106     DOI: 10.1016/s0008-6363(02)00664-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  18 in total

Review 1.  Protein kinase cascades in the regulation of cardiac hypertrophy.

Authors:  Gerald W Dorn; Thomas Force
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

2.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

Review 3.  Non-sarcomeric causes of heart failure: a Sydney Heart Bank perspective.

Authors:  C G Dos Remedios; A Li; S Lal
Journal:  Biophys Rev       Date:  2018-07-18

4.  Association between polymorphisms in the signal transducer and activator of transcription and dilated cardiomyopathy in the Chinese Han population.

Authors:  Ying Peng; Bin Zhou; Yanyun Wang; Yu Chen; Hui Li; Yaping Song; Lin Zhang; Li Rao
Journal:  Mol Cell Biochem       Date:  2011-09-23       Impact factor: 3.396

5.  Opposing actions of extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) in regulating microtubule stabilization during cardiac hypertrophy.

Authors:  Dominic C H Ng; Ivan H W Ng; Yvonne Y C Yeap; Bahareh Badrian; Tatiana Tsoutsman; Julie R McMullen; Christopher Semsarian; Marie A Bogoyevitch
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

6.  The reduced myofilament responsiveness to calcium contributes to the negative force-frequency relationship in rat cardiomyocytes: role of reactive oxygen species and p-38 map kinase.

Authors:  María Sofía Espejo; Ignacio Aiello; Marisa Sepúlveda; Martín G Vila Petroff; Ernesto A Aiello; Verónica C De Giusti
Journal:  Pflugers Arch       Date:  2017-08-23       Impact factor: 3.657

Review 7.  Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

Authors:  Sabzali Javadov; Sehwan Jang; Bryan Agostini
Journal:  Pharmacol Ther       Date:  2014-06-09       Impact factor: 12.310

Review 8.  PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?

Authors:  Jessica Lauriol; Maria I Kontaridis
Journal:  Trends Cardiovasc Med       Date:  2011-05       Impact factor: 6.677

9.  BNIP3 induces IL6 and calcineurin/NFAT3 hypertrophic-related pathways in H9c2 cardiomyoblast cells.

Authors:  Yi-Jiun Weng; Wei-Wen Kuo; Chia-Hua Kuo; Kwong-Chung Tung; Chang-Hai Tsai; James A Lin; Fuu-Jen Tsai; Dennis Jine-Yuan Hsieh; Chih-Yang Huang; Jin-Ming Hwang
Journal:  Mol Cell Biochem       Date:  2010-09-18       Impact factor: 3.396

10.  βIV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload.

Authors:  Sathya D Unudurthi; Drew Nassal; Amara Greer-Short; Nehal Patel; Taylor Howard; Xianyao Xu; Birce Onal; Tony Satroplus; Deborah Hong; Cemantha Lane; Alyssa Dalic; Sara N Koenig; Adam C Lehnig; Lisa A Baer; Hassan Musa; Kristin I Stanford; Sakima Smith; Peter J Mohler; Thomas J Hund
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.